Diltiazem XR Shortage: What Providers and Prescribers Need to Know in 2026

Your patients are calling. They can't fill their Diltiazem XR prescription, and they want to know if there's a shortage. As their prescriber, you need accurate, up-to-date information to make sound clinical decisions and keep patients safely on therapy. This briefing covers the current status, the structural factors driving supply disruptions, and practical strategies for managing Diltiazem XR access in your practice.

Current Status: What the Data Shows in 2026

As of early 2026, the FDA Drug Shortage Database does not list oral Diltiazem extended-release products as being in a declared national shortage. Multiple generic manufacturers — including Teva, Mylan (Viatris), Lupin, and Aurobindo — continue to supply the market.

However, the absence of a formal declaration does not mean supply is unimpeded. Providers should be aware of the following practical barriers:

Non-interchangeable ER formulations. Cardizem CD, Cardizem LA, Tiazac, Cartia XT, Dilacor XR, and Matzim LA each use different release mechanisms and are not AB-rated to each other. Pharmacists cannot substitute between them without a new prescription. This fragmentation creates effective shortages of specific formulation types even when other diltiazem products are in stock.

Strength-specific gaps. Higher strengths (300 mg, 360 mg, 420 mg) and certain common doses (120 mg, 360 mg) have experienced regional stock-outs.

Injectable shortage ongoing. Diltiazem hydrochloride injection (5 mg/mL) has been listed on the FDA shortage database since June 2015. Active suppliers include Hikma, Pfizer, Sagent, and Eugia, but allocation-based distribution continues. Hospitals should maintain substitution protocols.

Shortage Timeline: Key Milestones

June 2015: FDA first reports injectable diltiazem shortage; multiple manufacturers disrupted

2015–2021: Intermittent availability from Hospira/Pfizer, Hikma, and Akorn; ASHP maintains shortage listing

Mid-2022: Akorn Operating Company ceases operations, removing one of three diltiazem injection suppliers

2023–2024: Hikma places diltiazem 5 mg/mL vials on allocation; Sagent acquires Athenex's diltiazem line in June 2023

2025–2026: Injectable shortage continues; oral ER experiences localized pharmacy disruptions without formal FDA listing

Clinical Implications: The Non-Interchangeability Problem

The non-interchangeability of diltiazem ER formulations is the most clinically significant issue for outpatient prescribers in 2026. Patients may present reporting they cannot find their medication when, in fact, their pharmacy has a different diltiazem ER product on the shelf — just not their specific formulation type.

Providers can reduce this friction through several prescribing strategies:

Write for "DAW 0" (substitution permitted) when clinically appropriate, giving pharmacists flexibility to dispense AB-rated generics within the same formulation type

Be prepared to issue a new prescription for a different formulation type if the patient's current type is unavailable — convert to nearest equivalent total daily dose

Avoid specifying a brand name unless clinically necessary; "diltiazem ER capsules" gives pharmacists more working room than "Cartia XT"

IV Diltiazem Shortage: Hospital Protocols

For inpatient providers, the diltiazem injection shortage is an ongoing management challenge. With only a handful of active suppliers and allocation-based distribution expected to continue through 2026, hospitals should maintain current therapeutic substitution protocols. Common institutional IV alternatives include:

IV Esmolol — for acute rate control in supraventricular tachycardia

IV Metoprolol — for rate control, particularly in non-decompensated heart failure

IV Verapamil — for rate control and PSVT conversion

IV Amiodarone — for rate and rhythm control in more complex presentations

How to Help Your Patients Find Diltiazem XR

Directing patients to medfinder can significantly reduce the clinical burden on your practice. medfinder contacts pharmacies near patients to find which ones can fill their specific Diltiazem XR prescription — saving patients hours of calls and reducing call-backs to your office.

Consider adding medfinder to your patient handout materials or prescribing workflow for medications with known availability challenges.

For the patient-facing version of this update, see: Diltiazem XR Shortage Update: What Patients Need to Know in 2026.